PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 7, 2024. The event will begin at 1:30 p.m. PT and will conclude at approximately 3:30 p.m. PT.
Veeva will broadcast the presentations live on the company's investor relations website, ir.veeva.com, where a link to the archived webcast will also be available after the event.
Event: Veeva Systems 2024 Investor Day
Date: Thursday, November 7, 2024
Time: 1:30 p.m. PT (4:30 p.m. ET)
Online event registration can be found on the company's investor relations website or directly at this link.
Webcast: ir.veeva.com
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: | Media Contact: |
Gunnar Hansen | Maria Scurry |

| Last Trade: | US$218.10 |
| Daily Change: | 2.64 1.23 |
| Daily Volume: | 2,862,336 |
| Market Cap: | US$35.850B |
December 04, 2025 December 03, 2025 November 24, 2025 November 20, 2025 November 04, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load